These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 39191683)

  • 1. [Antibody-Drug Conjugates in Breast Cancer and Gynecologic Cancer].
    Saito A; Yonemori K
    Gan To Kagaku Ryoho; 2024 Jul; 51(7):695-701. PubMed ID: 39191683
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Next-generation antibody-drug conjugates for breast cancer: Moving beyond HER2 and TROP2.
    Schlam I; Moges R; Morganti S; Tolaney SM; Tarantino P
    Crit Rev Oncol Hematol; 2023 Oct; 190():104090. PubMed ID: 37562695
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The evolving landscape of antibody-drug conjugates in gynecologic cancers.
    Tolcher A; Hamilton E; Coleman RL
    Cancer Treat Rev; 2023 May; 116():102546. PubMed ID: 37023499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody-Drug Conjugates in Gynecologic Cancer.
    Karpel HC; Powell SS; Pothuri B
    Am Soc Clin Oncol Educ Book; 2023 May; 43():e390772. PubMed ID: 37229642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrating antibody drug conjugates in the management of gynecologic cancers.
    Chelariu-Raicu A; Mahner S; Moore KN; Lorusso D; Coleman RL
    Int J Gynecol Cancer; 2023 Mar; 33(3):420-429. PubMed ID: 36878560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody-Drug Conjugates in Gynecologic Cancers.
    Anastasio MK; Shuey S; Davidson BA
    Curr Treat Options Oncol; 2024 Jan; 25(1):1-19. PubMed ID: 38172449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel antibody-drug conjugates: current and future roles in gynecologic oncology.
    Tymon-Rosario J; Zeybek B; Santin AD
    Curr Opin Obstet Gynecol; 2021 Feb; 33(1):26-33. PubMed ID: 32618744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions.
    Ferraro E; Drago JZ; Modi S
    Breast Cancer Res; 2021 Aug; 23(1):84. PubMed ID: 34380530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in antibody-drug conjugates for gynecologic malignancies.
    Tymon-Rosario J; Gorman M; Richardson DL; Washington C; Santin AD
    Curr Opin Obstet Gynecol; 2023 Feb; 35(1):6-14. PubMed ID: 36484278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The target invites a foe: antibody-drug conjugates in gynecologic oncology.
    Campos MP; Konecny GE
    Curr Opin Obstet Gynecol; 2018 Feb; 30(1):44-50. PubMed ID: 29227302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sequencing Antibody Drug Conjugates in Breast Cancer: Exploring Future Roles.
    Fenton MA; Tarantino P; Graff SL
    Curr Oncol; 2023 Nov; 30(12):10211-10223. PubMed ID: 38132377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody-drug conjugates in lung and breast cancer: current evidence and future directions-a position statement from the ETOP IBCSG Partners Foundation.
    Peters S; Loi S; André F; Chandarlapaty S; Felip E; Finn SP; Jänne PA; Kerr KM; Munzone E; Passaro A; Pérol M; Smit EF; Swanton C; Viale G; Stahel RA
    Ann Oncol; 2024 Jul; 35(7):607-629. PubMed ID: 38648979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Leveraging TROP2 Antibody-Drug Conjugates in Solid Tumors.
    Nelson BE; Meric-Bernstam F
    Annu Rev Med; 2024 Jan; 75():31-48. PubMed ID: 37758237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody-Drug Conjugates for Breast Cancer Treatment: Emerging Agents, Targets and Future Directions.
    Yang T; Li W; Huang T; Zhou J
    Int J Mol Sci; 2023 Jul; 24(15):. PubMed ID: 37569276
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent Advances in Antibody-Drug Conjugates for Breast Cancer Treatment.
    Deng S; Lin Z; Li W
    Curr Med Chem; 2017; 24(23):2505-2527. PubMed ID: 28554322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody-Drug Conjugates (ADC) in HER2/neu-Positive Gynecologic Tumors.
    McNamara B; Greenman M; Pebley N; Mutlu L; Santin AD
    Molecules; 2023 Nov; 28(21):. PubMed ID: 37959808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody-Drug Conjugates in Breast Cancer: Ascent to Destiny and Beyond-A 2023 Review.
    Xiao T; Ali S; Mata DGMM; Lohmann AE; Blanchette PS
    Curr Oncol; 2023 Jul; 30(7):6447-6461. PubMed ID: 37504334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advancing antibody-drug conjugates in gynecological malignancies: myth or reality?
    Nerone M; Grande MD; Sessa C; Colombo I
    Explor Target Antitumor Ther; 2022; 3(2):149-171. PubMed ID: 36046840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody-Drug Conjugates in Breast Cancer: What Is Beyond HER2?
    Nicolò E; Repetto M; Boscolo Bielo L; Tarantino P; Curigliano G
    Cancer J; 2022 Nov-Dec 01; 28(6):436-445. PubMed ID: 36383906
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The DNA repair pathway as a therapeutic target to synergize with trastuzumab deruxtecan in HER2-targeted antibody-drug conjugate-resistant HER2-overexpressing breast cancer.
    Lee J; Kida K; Koh J; Liu H; Manyam GC; Gi YJ; Rampa DR; Multani AS; Wang J; Jayachandran G; Lee DW; Reuben JM; Sahin A; Huo L; Tripathy D; Im SA; Ueno NT
    J Exp Clin Cancer Res; 2024 Aug; 43(1):236. PubMed ID: 39164784
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.